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A lean and mean VEGF for cancer cells
C
ells that suffer DNA damage start pumping out a previ-
ously undiscovered version of the angiogenesis promoter 
VEGF, as Mineur et al. report. The variant, which is tough 
and mobile, might help cancer cells tap new sources of blood.
Researchers have already nabbed about 10 versions of 
VEGF, which many cancer cells overproduce to feed their need for 
blood. Mineur et al. were studying the effects of UV light on cells 
when they stumbled across another variant that lacks three of the 
eight standard VEGF exons. The new version, which the researchers 
dubbed VEGF111, forms in cells exposed to UV radiation or 
DNA-breaking compounds such as camptothecin. Those results 
suggest that the VEGF111 results from DNA damage.
VEGF111 is short but sturdy; it lacks the region that’s 
vulnerable to protein-slicing enzymes such as plasmin, making 
it harder to break down. The variant is also missing the VEGF 
section that interacts with the extracellular matrix (ECM). That 
loss might boost VEGF111’s mobility because it wouldn’t get 
snared as it diffuses through the ECM.
The researchers didn’t detect the new variant in cells 
from healthy mice and people, or in animals dosed with UV 
light or camptothecin, perhaps because the variant is rare. But 
tumor cells transplanted into mice that received camptothecin 
did manufacture VEGF111. To gauge the molecule’s effects on 
angiogenesis, the team injected 
mice with tumor cells that fashioned 
one of three VEGF versions, 
including VEGF111. All three types 
of the growth factor spurred 
formation of new blood vessels. 
These vessels covered the tumors 
that made the two other VEGF 
isoforms, but they sprouted a short 
distance away from growths that 
produced VEGF111. The reason 
for this difference isn’t clear.
Because it’s durable and 
forms in response to DNA dam-
age, such as that caused by che-
motherapy, VEGF111 could be a 
formidable foe. It might help can-
cer cells resist drugs, for instance. 
On the other hand, the molecule 
could spur new treatments for conditions in which angiogen-
esis is desperately needed, such as heart attacks and non-
healing wounds. 
Reference: Mineur, P., et al. 2007. J. Cell Biol. 179:1261–1273.
Microglia to the rescue
I
mmune cells fi  ght a losing battle against a harmful 
abnormal protein found in some cases of amyotrophic 
lateral sclerosis (ALS), as Kang and Rivest report. The 
fi  ndings support the hypothesis that extracellular accumula-
tions of faulty proteins trigger the disease’s neural damage.
Researchers aren’t sure why muscle-controlling motor 
neurons deteriorate in ALS. Patients with the inherited 
form of the disease carry mutations in the gene for the 
antioxidant enzyme SOD1. But how defective SOD1 
causes neurodegeneration remains uncertain. One 
possibility is that the altered SOD1 builds up outside 
neurons and eventually kills them. Several studies 
suggest that some neighboring cells can shield neurons from the protein’s ill effects. Kang and Rivest 
tested whether microglia, the main infection-combating cells in the brain, were protective.
The researchers transplanted bone marrow with labeled cells into two mouse strains that manufacture differ-
ent forms of mutant human SOD1. In both strains, the cells swarmed from the marrow to the brain, presumably 
to attack the SOD1. Injecting defective SOD1 into the brains of normal animals also drew a crowd of microglia. 
The team found that SOD1 activated microglia, but not if the cells lacked an adapter protein called MyD88.
To probe MyD88’s role, the researchers implanted bone marrow lacking the protein into mice from the two 
strains. In one strain, MyD88-defi  ciency caused the animals to develop symptoms sooner and to die nearly 
two months earlier. In the other stain, however, losing MyD88 signaling had no effect on survival. It’s possible 
that the SOD1 variant in this strain kills the animals so quickly that the transplants didn’t have time to help.
The study suggests that microglia from the bone marrow protect neurons from toxic buildups of mutant 
SOD1. But if microglia are on the job, why do the animals still die? The researchers hypothesize that, 
although microglia can keep faulty SOD1 in check temporarily, the immune system eventually tires, 
allowing lethal amounts of the protein to accumulate. 
Reference: Kang, J., and S. Rivest. 2007. J. Cell Biol. 179:1219–1230.
More blood vessels sprout 
on cell clusters that fashion 
VEGF111 (bottom).
In two strains of mice with SOD1 mutations, the brain teems with microglia 
from the bone marrow (yellow).